



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Re the Application of GRILLO-LOPEZ et al.
Application No.: 09/436,348

Group Art Unit: 1644

Examiner: Ronald Schwadron

Filed: November 9, 1999

For: USE OF CHIMERIC ANTI-CD20 ANTIBODY AS IN VITRO IN VIVO PURGING
GENT IN PATIENTS RECEIVING BMT OR PBSC TRANSPLANT

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents
P. O. Box 1450
Alexandria, VA 22313-1450

Sir:

Pursuant to 37 CFR 1.56, the attention of the U.S. Patent and Trademark Office is hereby directed to the reference(s) listed on the attached PTO-1449. Unless otherwise indicated, one copy of each reference is attached. It is respectfully requested that the information be expressly considered during the prosecution of this application, and that the references be made of record therein and appear among the "References Cited" on any patent to issue therefrom.

This Information Disclosure Statement is being filed more than three months after the U.S. filing date and before the mailing date of the first official action on the merits. No certification fee is required.


Respectfully Submitted,

A handwritten signature in black ink, appearing to read "TAC".

Thomas A. Cawley, Jr., Ph.D.
Registration Number 40,944
Customer Number: 5272

Date: October 24, 2003
PILLSBURY WINTHROP LLP
Telephone: (703) 905-2000
Facsimile: (703) 905-2500
P.O. Box 10500
McLean, VA 22102
TAC/JBM:ntb

FORM PTO-1449 (modified)
 To: U.S. Department of Commerce
 (PW FORM PAT-1449)
 Patent and Trademark Office



Atty. Dkt. No.	M#	Client Ref.
	0275537	1998-30-0524A
Applicant: GRILLO-LOPEZ et al.		
Appln. No.: 09/436,348		
Filing Date: November 9, 1999		
Examiner: R. Schwadron		Group Art Unit: 1644

Date: October 24, 2003

Page **1** of **1**

U.S. PATENT DOCUMENTS

Examiner's Initials*	Document Number	Date MM/YYYY	Name (Family Name of First Inventor)	Class	Sub Class	Filing Date (if appropriate)
AR	5,530,101	06/1996	Queen et al.			
BR	5,225,539	07/1993	Winter et al.			
CR	4,816,397	03/1989	Boss et al.			
DR	4,816,567	03/1989	Cabilly et al.			
ER	5,500,362	03/1996	Robinson et al.			
FR	5,736,137	04/1988	Anderson et al.			
GR	6,183,744	02/2001	Goldenberg			
HR	6,306,393	10/2001	Goldenberg			
IR						
JR						
KR						
LR						
MR						
NR						

FOREIGN PATENT DOCUMENTS

	Document Number	Date MM/YYYY	Country	Inventor Name		English Abstract	Translation Readily Available
						Enclosed	No
OR							
PR							
QR							
RR							
SR							
TR							
UR							
VR							

OTHER (Including in this order Author, Title, Periodical Name, Date, Pertinent Pages, etc.)

WR	McLaughlin et al., Rituximab® chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a 4-dose treatment program, (1998), <i>J Clin Oncology</i> , 16:2825-2833.
XR	McLaughlin et al., Efficacy controls in long-term follow-up patients treated with rituximab for relapsed or refractory, low-grade or follicular NHL, (1998), <i>Blood</i> , 92:414a-415a.
YR	Janakiraman et al., Rituximab: Correlation between effector cells and clinical activity in NHL, (1998), <i>Blood</i> , 92(10 suppl 1):337a.
ZR	Rottenburger et al., Clonotypic CD20+ and CD19+ B cells in peripheral blood of patients with multiple myeloma post high-dose therapy and peripheral blood stem cell transplantation, (1999), <i>Br J Haematol.</i> , 106(2):545-552.

Examiner	Date Considered:
*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.	